German drugmaker Merck KGaA agreed to acquire Silence Therapeutics for $1.3 billion to enhance its gene silencing capabilities. The all-cash deal values shares at $20 each and is scheduled to close in
Merck KGaA has acquired PostEra’s two oral fertility molecule programs in a deal worth mid-double-digit millions. This move capitalizes on PostEra's recent strategic shift toward developing drug candi
Merck KGaA has entered a definitive agreement to acquire Bio-Techne Corp for $73 per share in cash, totaling approximately $11.3 billion. The transaction offers a 36% premium over Bio-Techne's recent
Merck KGaA has agreed to acquire Bio-Techne Corp for $11.3 billion to expand its life-science research capabilities. The deal includes research reagents, proteins, and antibodies, funded via cash and
ChemBrief